News

Selinexor Maintenance Therapy Improved PFS Among Patients With TP53 Wild-Type Advanced or Recurrent Endometrial Cancer

10/12/2023

Stephanie Holland

Results from an exploratory analysis of the ENGOT-EN5/GOG-3055/SIENDO study identified that selinexor maintenance therapy improved PFS among patients with TP53 wild-type advanced or recurrent endometrial cancer.

Results from an exploratory...

10/12/2023

Oncology

News

Statistical Significance, Prognostic Precision of 2023 FIGO Staging System for Pre-Treated, Early-Stage Endometrial Cancer

09/19/2023

Stephanie Holland

According to results of a retrospective study, the 2023 FIGO staging system led to statistically significant stage shifts and higher prognostic precision among patients with pre-treated, early-stage endometrial cancer.

According to results of a...

09/19/2023

Oncology

News

Molecular Classification Predicts Radiotherapy Benefit in Early-Stage Endometrioid Endometrial Cancer

08/29/2023

Stephanie Holland

According to an analysis of data from the PORTEC-1 and PORTEC-2 trials, molecular classification can predict response to radiotherapy in early-stage endometrioid endometrial cancer.

According to an analysis of data...

08/29/2023

Oncology

News

Selinexor Maintenance Therapy Demonstrated Durable PFS Benefit Among Patients With Advanced or Recurrent TP53 Wild-Type Endometrial Cancer

08/10/2023

Stephanie Holland

According to long-term follow-up results from the phase 3 SIENDO trial, selinexor maintenance prior to systemic therapy showed durable PFS benefit among patients with advanced or recurrent TP53wt endometrial cancer.

According to long-term follow-up...

08/10/2023

Oncology

News

Dostarlimab With Carboplatin–Paclitaxel Prolonged Progression-Free Survival Among Patients With Primary Advanced or Recurrent Endometrial Cancer

08/02/2023

Amber Denham

Dostarlimab with carboplatin–paclitaxel significantly increased progression-free survival among patients with primary advanced or recurrent endometrial cancer.

Dostarlimab with...

08/02/2023

Oncology

News

FDA Approves Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent dMMR/MSI-H Endometrial Cancer

08/01/2023

Stephanie Holland

Based on findings from the RUBY trial, the FDA has approved dostarlimab-gxly plus carboplatin and paclitaxel for adult patients with advanced or recurrent dMMR/MSI-H endometrial cancer.

Based on findings from the RUBY...

08/01/2023

Oncology

News

Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer

07/24/2023

Amber Denham

The combination of pembrolizumab with standard chemotherapy resulted in significantly longer progression-free survival among patients with advanced or recurrent endometrial cancer, compared with chemotherapy alone.

The combination of pembrolizumab...

07/24/2023

Oncology

Mansoor Raza Mirza, MD, Copenhagen University Hospital, Denmark

Conference Coverage

Beyond Immunotherapy Treatment for Patients With Recurrent Metastatic Endometrial Cancer

02/24/2023

At the 2023 ESMO Gynecological Cancers Congress, Mansoor Raza Mirza, MD, discusses the role of HER2, p53, and other molecular targets in treating patients with recurrent, metastatic endometrial cancer.

At the 2023 ESMO Gynecological...

02/24/2023

Oncology

News

Lenvatinib Plus Pembrolizumab Demonstrates Long-Term Efficacy, Safety in Advanced Endometrial Carcinoma

02/16/2023

Derek Cowsert

Updated study results find lenvatinib plus pembrolizumab exhibits long-term safety and efficacy for patients with previously treated advanced endometrial carcinoma.

Updated study results find...

02/16/2023

Oncology

News

FDA Approves Dostarlimab for Mismatch Repair Deficient Recurrent or Advanced Endometrial Cancer

02/10/2023

On February 9, 2023, the FDA approved dostarlimab-gxly for adult patients with mismatch repair deficient recurrent or advanced endometrial cancer.

On February 9, 2023, the FDA...

02/10/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology